City of Hope Recovers Rights to CHM 1101, a CAR-T Therapy for Glioblastoma, from Chimeric Therapeutics (CHM.AX)
Chimeric Therapeutics Returns CLTX-CAR T Asset and Restructures Portfolio
Australian biotech Chimeric Therapeutics (CHM.AX) has returned the rights to CHM 1101, a chimeric antigen receptor T-cell (CAR T-cell) therapy targeting chlorotoxin (CLTX) for glioblastoma, to its original developer, City of Hope Medical Center, as part of a portfolio adjustment effective February 27, 2026. This strategic decision by management aims to maximize capital efficiency by prioritizing the development of its gastrointestinal cancer-targeted pipeline, CHM CDH17. The agreement eliminates Chimeric Therapeutics' future milestone and royalty obligations related to clinical progress, thereby reducing financial risk.
Unique Mechanism and Value of Chlorotoxin-Targeting Technology
CHM 1101 is a first-in-class CAR-T cell therapy that utilizes chlorotoxin, a peptide derived from Deathstalker scorpion venom, as its targeting domain. This therapy exhibits a unique mechanism of action, binding with high affinity to matrix metalloproteinase-2 (MMP-2), an enzyme overexpressed on the surface of glioblastoma (GBM) cells, leading to their destruction. Specifically, it employs an intracranial route (intracranial administration, including intraventricular and intratumoral delivery) to directly administer cells, leveraging a precision medicine strategy designed to overcome the heterogeneous environment and blood-brain barrier (BBB) characteristic of brain tumors.
Safety and Efficacy Demonstrated in Phase 1 Data
Preliminary data from a Phase 1 clinical trial (NCT04214392) conducted by City of Hope demonstrated the excellent safety and promising efficacy of CHM 1101. Approximately 70% of patients with recurrent and progressive glioblastoma who participated in the trial achieved a disease control rate (DCR), indicating tumor growth inhibition. The median overall survival in this patient group was approximately 10 months, with some patients exhibiting long-term survival exceeding 14 months. Based on these encouraging clinical results, a multi-center Phase 1b trial (NCT05627323) was approved to evaluate dose escalation.
Competitive Landscape and Future Prospects of the Glioblastoma Treatment Market
The global glioblastoma market is estimated at approximately USD 3.5 to 4 billion in 2025 and is projected to reach up to USD 8.3 billion by 2033-2035, representing a significant market opportunity. The current standard of care, temozolomide chemotherapy or Avastin targeted therapy, offers limited survival benefits for recurrent patients, resulting in a high unmet medical need. Although Chimeric Therapeutics' asset transfer results in a short-term change in the commercialization entity, the original developer, City of Hope, will continue independent clinical development, preserving the technology's potential as a next-generation immuno-oncology platform.
With the glioblastoma (GBM) market reaching up to USD 4 billion in 2025 and the limitations of existing treatments, the Phase 1 data for CHM 1101, demonstrating a DCR of 70% and a median survival of 10 months, suggests a potential breakthrough for CAR-T therapy in solid tumors. Chimeric Therapeutics' (CHM.AX) decision to return the asset development rights to City of Hope, eliminating milestone expenditure obligations, provides short-term financial flexibility and allows the company to focus on other pipeline assets. The industry is closely watching whether the scorpion venom-derived chlorotoxin (CLTX) targeting MMP-2 can overcome the heterogeneity of brain tumors. In the medium to long term, the safety of the intracranial direct administration method compared to Mustang Bio's MB-101 and the achievement of a Phase 2 recommended Phase 2 dose (RP2D) will be key indicators. From an investor perspective, it is crucial to closely monitor the impact of this asset transfer on the future independent clinical development and the demonstration of platform value.
Source: ClinicalTrials.gov (api_ct)